| Nov 14 |
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
|
| Nov 7 |
Zura Bio GAAP EPS of -$0.26 misses by $0.13
|
| Nov 7 |
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
|
| Oct 30 |
Zura Bio to Participate in Two Upcoming Investor Conferences in November
|
| Oct 17 |
Bullish Zura Bio Insiders Loaded Up On US$1.01m Of Stock
|
| Sep 20 |
Institutions profited after Zura Bio Limited's (NASDAQ:ZURA) market cap rose US$45m last week but private equity firms profited the most
|
| Sep 3 |
Zura Bio files for $300M mixed securities shelf
|
| Sep 3 |
Zura Bio to Present at Three Upcoming Investor Conferences in September
|
| Aug 15 |
We're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Rate
|
| Aug 14 |
Zura Bio GAAP EPS of -$0.17
|
